Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Charity 'feels the pinch' of higher energy prices - 2New research reveals urban raccoons across the US show early signs of domestication
- 3A definitive Handbook for Securities exchange Money management
- 4Shakira's 2026 'Las Mujeres Ya No Lloran' U.S. Tour: How to get tickets, prices, dates and more
- 5Sexual violence is being used as a weapon in Sudan's war, doctors group says
- The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds
- Canada cancels its 1st moon rover: 'It's hopefully not a lost cause'
- NASA Perseverance rover sees megaripples on Mars | Space photo of the day for Jan. 7, 2026.
- New COVID-19 variant 'Cicada' is spreading. What to know about BA.3.2.
- 21 Things You Ought to Never Share with Your Childless Companion
- Employers and staff feel effect of fuel price rise
- Astronauts head home early after medical issue
